Adaptive Biotechnologies Corp. (ADPT) reported that its net loss for the second quarter of 2024 narrowed to $46.2 million or $0.31 per share from $47.8 million or $0.33 per share in the prior year.
Revenue for the second quarter was $43.2 million, representing a 12% decrease from the second quarter in the prior year. MRD revenue was $35.3 million for the quarter, representing a 36% increase from the second quarter in the prior year.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.33 per share and revenues of $38.66 million for the second quarter. Analysts' estimates typically exclude special items.
Adaptive Biotechnologies expects full year revenue for the MRD business to be between $140 million and $145 million, updated from the previous range between $135 million and $140 million. No revenue guidance is provided for the Immune Medicine business.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.